| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000011752 |
| Receipt No. | R000013739 |
| Official scientific title of the study | Prospective, randomized, open-label, clinical trial evaluating the effects of dipeptidyl peptidase-4 (DPP4) inhibitors on progression of atherosclerotic plaques and endothelial function in type 2 diabetic patients |
| Date of disclosure of the study information | 2013/09/14 |
| Last modified on | 2018/05/24 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Prospective, randomized, open-label, clinical trial evaluating the effects of dipeptidyl peptidase-4 (DPP4) inhibitors on progression of atherosclerotic plaques and endothelial function in type 2 diabetic patients | |
| Title of the study (Brief title) | Clinical trial evaluating the effects of dipeptidyl peptidase-4 (DPP4) inhibitors | |
| Region |
|
|
| Condition | ||
| Condition | type 2 diabetes | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare therapies with or without DPP4 inhibotors on atherosclerotic plaques progression and endothelial function in type 2 diabetic patients |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | (1) Area and thickness of atherosclerotic plaques in aorta detected by magnetic resonance imaging (MRI)
12/24 months after randomization (2) Flow-mediated vasodilation in forearm 6 months after randomization |
| Key secondary outcomes | (1) Ankle/brachial index and cardio ankle vascular index
(2) Markers for diabetes (hemoglobin A1c, glycoalbumin, blood glucose) (3) Serum lipids (4) Markers indicating obesity (e.g. adiponectin) (5) Markers indicating inflammation (e.g. high sensitive CRP) (6) Markers indicating oxidative stress (8-OHdG/ MDA-LDL) (7) Markers indicating chronic renal diseases (urine albumin/L-FABP) (8) Blood/urine urate levels (9) Body weight/waist circumference (10) blood pressures |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Treatment for type 2 diabetes with DPP4 inhibitors | |
| Interventions/Control_2 | Treatment for type 2 diabetes without DPP4 inhibitors | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Type 2 diabetic patients who should be treated with anti-diabetic agents recommended by Japan Diabetes Society Guidelines
2) Patients who have aortic atherosclerotic plaques detected by MRI 3) Outpatients 4) Subjects who gave written informed consent |
|||
| Key exclusion criteria | 1) Allergy against DPP4 inhibitors
2) Type 1 diabetes or patients with positive anti-islet antibodies 3) Secondary diabetes 4) Poor-controlled diabetes (HbA1c>10.0 %) 5) Under administration of DPP-4 inhibitors or GLP-1 agonists 6) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months 7) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits 8) End stage renal disease 9) Symptomatic (NYHA III or IV) congestive heart failure 10) Malignancies or other diseases with poor prognosis 11) Pregnant 12) Subjects whose doctor in charge do not agree to join the trial |
|||
| Target sample size | 66 | |||
| Research contact person | |
| Name of lead principal investigator | Katsunori Ikewaki |
| Organization | National Defense Medical College |
| Division name | Department of Internal Medicine |
| Address | 3-2 Namiki, Tokorozawa, JAPAN 359-8513 |
| TEL | 04-2995-1617 |
| katsunorike@ndmc.ac.jp | |
| Public contact | |
| Name of contact person | Makoto Ayaori |
| Organization | National Defense Medical College |
| Division name | Department of Internal Medicine |
| Address | 3-2 Namiki, Tokorozawa, JAPAN 359-8513 |
| TEL | 04-2995-1617 |
| Homepage URL | |
| ayaori@ndmc.ac.jp | |
| Sponsor | |
| Institute | National Defense Medical College |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Foundation for Promotion of Defense Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013739 |